Skip to main content

Advertisement

Table 1 Patient baseline characteristics

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

  GEM-E (n = 1,331) GEM (n = 2,936) p-valuea
No. (%) No. (%)
Sex
 Male 861 (64.69) 1,743 (59.37) 0.0010
 Female 470 (35.31) 1,193 (40.63)  
Age, years
 Mean ± SD 61.89 ± 9.76 63.38 ± 10.40 <0.0001
 Median 63 65  
 Range 28–88 18–92  
 18–29 2 (0.15) 6 (0.20) <0.0001
 30–39 16 (1.20) 42 (1.43)  
 40–49 128 (9.62) 268 (9.13)  
 50–59 387 (29.08) 683 (23.26)  
 60–69 486 (36.51) 1,010 (34.4)  
 70–79 295 (22.16) 825 (28.1)  
 Above 80 17 (1.28) 102 (3.47)  
Charlson Comorbidity Index (CCI)
 Mean ± SD 8.88 ± 3.39 9.14 ± 3.40 0.0206
 Median 10 10  
 Range 2–18 2–19  
Comorbidity score
  ≤ 3 102 (7.66) 222 (7.56) 0.2024
 4–6 246 (18.48) 476 (16.21)  
 7–9 302 (22.69) 664 (22.62)  
 10–12 511 (38.39) 1,134 (38.62)  
  ≥ 13 170 (12.77) 440 (14.99)  
Follow-up time, daysb
 Mean ± SD 278.7 ± 224.7 292.3 ± 263.3  
 Median 210 207  
  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
  2. aDifferences between GEM and GME-E were tested with t-test for continues variable and with the chi-square test for categorical variables
  3. bFollow-up termination: follow-up for 3 years or until December 31, 2013 or date of death